|This Slide: #75 of 100|
Slide #75. Charles River Laboratories — CRO Services Division of Galapagos NV
Charles River Laboratories (NYSE:CRL)
CRO Services Division of Galapagos NV
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has entered into a definitive agreement to acquire the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. These businesses are global leaders in integrated drug discovery services, with a predominant focus on in vitro capabilities. The acquisition will position Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.
Charles River Laboratories International is a contract research organization engaged in laboratory animal medicine and science to develop a portfolio of discovery and safety assessment services. Co. has three reportable segments: Research Models and Services, which supplies research models to the drug development industry; Discovery and Safety Assessment, which provides discovery and safety assessment services that include both in vivo and in vitro studies, supporting laboratory services, and non-clinical consulting and program management to support product development; and Manufacturing Support, which includes its microbial solutions, avian vaccine services and biologics testing solutions.
CRL SEC Filing Email Alerts Service
Open the CRL Page at The Online Investor »
Buy (3.40 out of 4)
(ranked higher than approx. 58% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite